ISDA

Entry Detail

PDB ID:

4PY1

Keywords:

Title:

Crystal structure of Tyk2 in complex with compound 15, 6-((2,5-dimethoxyphenyl)thio)-3-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazine

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2014-03-25

Release Date:

2014-09-03

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.16 Å

R-Value Free:

0.23

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Non-receptor tyrosine-protein kinase TYK2
Mutations:C936A, Q969A, E971A, K972A, C1142A
Chain IDs:A
Chain Length:318
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P29597 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	O-PHOSPHOTYROSINE

Ligand Molecules

2YK

Primary Citation

Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.

Galatsis, P, Henderson, J.L, Kormos, B.L, Han, S, Kurumbail, R.G, Wager, T.T, Verhoest, P.R, Noell, G.S, Chen, Y, Needle, E, Berger, Z, Steyn, S.J, Houle, C, Hirst, W.D.Show

Bioorg.Med.Chem.Lett. 24 4132 4140 (2014)

PMID: 25113930 DOI: 10.1016/j.bmcl.2014.07.052

Abstact

Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the structure, potential ligand-protein binding interactions, and pharmacological profiling of potent and highly selective kinase inhibitors based on a triazolopyridazine chemical scaffold.

Legend

Protein

Chemical

Disease

Primary Citation of related structures